巴雷特食管的生物标志物。
Biomarkers of Barrett's esophagus.
作者信息
Fouad Yasser Mahrous, Mostafa Ibrahim, Yehia Reem, El-Khayat Hisham
机构信息
Yasser Mahrous Fouad, Reem Yehia, Gastroenterology and Hepatology Unit, Tropical Medicine Department, Minia University, Minia 11432, Egypt.
出版信息
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):450-6. doi: 10.4291/wjgp.v5.i4.450.
Abstract
Barrett's esophagus is the strongest risk for esophageal adenocarcinoma (EAC). Metaplasia in patients with BE may progress to dysplasia and then invasive carcinoma. Well-defined diagnostic, progressive, predictive, and prognostic biomarkers are needed to identify the presence of the disease, estimate the risk of malignant transformation, and predict the therapeutic outcome and survival of EAC patients. There are many predictive and prognostic markers that lack substantial validation, and do not allow stratification of patients with gastroesophageal reflux disease in clinical practice for outcome and effectiveness of therapy. In this short review we summarize the current knowledge regarding possible biomarkers, focusing on the pathophysiologic mechanisms to improve prognostic and therapeutic approaches.
摘要
巴雷特食管是食管腺癌（EAC）最强的风险因素。巴雷特食管患者的化生可能进展为发育异常，进而发展为浸润性癌。需要明确的诊断、进展、预测和预后生物标志物来识别疾病的存在、估计恶性转化的风险，并预测EAC患者的治疗结果和生存率。有许多预测和预后标志物缺乏充分验证，在临床实践中无法对胃食管反流病患者进行分层以评估治疗结果和疗效。在这篇简短的综述中，我们总结了关于可能的生物标志物的现有知识，重点关注改善预后和治疗方法的病理生理机制。
相似文献
1
Biomarkers of Barrett's esophagus.
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):450-6. doi: 10.4291/wjgp.v5.i4.450.
2
Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.
Updates Surg. 2018 Sep;70(3):339-342. doi: 10.1007/s13304-018-0564-y. Epub 2018 Jul 23.
3
Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Ann Surg. 2004 Jun;239(6):849-56; discussion 856-8. doi: 10.1097/01.sla.0000128303.05898.ee.
4
GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
Gastroenterol Res Pract. 2013;2013:643084. doi: 10.1155/2013/643084. Epub 2013 Mar 20.
5
The diagnosis and management of Barrett's esophagus.
Adv Surg. 1999;33:29-68.
6
Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Surg Endosc. 2015 Dec;29(12):3528-34. doi: 10.1007/s00464-015-4103-3. Epub 2015 Feb 13.
7
8
The value of medical imaging in uncomplicated and complicated Barrett's esophagus.
Acta Gastroenterol Belg. 2000 Jan-Mar;63(1):22-8.
9
Barrett's esophagus and risk of esophageal adenocarcinoma.
Semin Gastrointest Dis. 2003 Jul;14(3):128-35.
10
Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
Pathol Int. 2014 Aug;64(8):397-401. doi: 10.1111/pin.12181.
引用本文的文献
1
EsoDetect: computational validation and algorithm development of a novel diagnostic and prognostic tool for dysplasia in Barrett's esophagus.
PeerJ. 2025 Jul 3;13:e19613. doi: 10.7717/peerj.19613. eCollection 2025.
2
The Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett's Esophagus-Dysplasia.
Cancers (Basel). 2024 Jun 28;16(13):2386. doi: 10.3390/cancers16132386.
3
Molecules involved in the development of Barrett's esophagus phenotype in chronic eosinophilic esophagitis.
Am J Physiol Gastrointest Liver Physiol. 2022 Jul 1;323(1):G31-G43. doi: 10.1152/ajpgi.00321.2021. Epub 2022 Apr 19.
4
Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.
J Gastrointest Oncol. 2021 Aug;12(4):1197-1214. doi: 10.21037/jgo-21-117.
5
Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.
Clin J Gastroenterol. 2020 Oct;13(5):635-649. doi: 10.1007/s12328-020-01135-2. Epub 2020 Jun 3.
6
Role of Mitochondrial Markers in Improved Detection and Risk-Stratification in Barrett's Esophagus Patients.
Yale J Biol Med. 2019 Sep 20;92(3):533-539. eCollection 2019 Sep.
7
Challenges in Endoscopic Therapy of Dysplastic Barrett's Esophagus.
Curr Treat Options Gastroenterol. 2019 Mar;17(1):32-47. doi: 10.1007/s11938-019-00215-8.
8
Barrett's oesophagus: Current controversies.
World J Gastroenterol. 2017 Jul 28;23(28):5051-5067. doi: 10.3748/wjg.v23.i28.5051.
9
LYN, a Key Gene From Bioinformatics Analysis, Contributes to Development and Progression of Esophageal Adenocarcinoma.
Med Sci Monit Basic Res. 2015 Dec 21;21:253-61. doi: 10.12659/MSMBR.895463.
10
Gastroesophageal reflux and congenital gastrointestinal malformations.
World J Gastroenterol. 2015 Jul 28;21(28):8508-15. doi: 10.3748/wjg.v21.i28.8508.
本文引用的文献
1
GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
Gastroenterol Res Pract. 2013;2013:643084. doi: 10.1155/2013/643084. Epub 2013 Mar 20.
2
Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia.
PLoS One. 2012;7(5):e37571. doi: 10.1371/journal.pone.0037571. Epub 2012 May 22.
3
p16 gene mutations in Barrett's esophagus in gastric metaplasia - intestinal metaplasia - dysplasia - adenocarcinoma sequence.
Adv Med Sci. 2012 Jun 1;57(1):71-6. doi: 10.2478/v10039-012-0003-0.
4
Barrett's esophagus: progression to adenocarcinoma and markers.
Ann N Y Acad Sci. 2011 Sep;1232:210-29. doi: 10.1111/j.1749-6632.2011.06053.x.
5
Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
Am J Gastroenterol. 2011 Jan;106(1):46-56. doi: 10.1038/ajg.2010.433. Epub 2010 Dec 14.
6
Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.
World J Gastroenterol. 2010 Dec 7;16(45):5669-81. doi: 10.3748/wjg.v16.i45.5669.
7
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.
Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97. doi: 10.1158/1940-6207.CAPR-10-0108. Epub 2010 Oct 12.
8
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study.
BMJ. 2010 Sep 10;341:c4372. doi: 10.1136/bmj.c4372.
9
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.
Gastroenterology. 2010 Dec;139(6):1995-2004.e15. doi: 10.1053/j.gastro.2010.05.080. Epub 2010 Jun 2.
10
Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy.
Br J Cancer. 2010 May 25;102(11):1608-17. doi: 10.1038/sj.bjc.6605688. Epub 2010 May 11.
Zotero 插件